• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血液科医生视角下的风险管理

[Risk management from the perspective of the hematologist].

作者信息

Gossrau Elke

机构信息

DRK-Blutspendedienst Berlin gGmbH, Berlin.

出版信息

Z Arztl Fortbild Qualitatssich. 2003 Nov;97(8-9):618-21.

PMID:14710657
Abstract

The present paper deals with the physician's accountability during the implementation of hemotherapeutic measures. Since July 1, 1998 a Transfusion Law ('Transfusionsgesetz') regulates the clinical use of blood products in Germany in accordance with the guidelines established by the German Medical Association and the Paul Ehrlich Institute, which are regularly revised and adapted on the basis of current professional knowledge and technology. The therapeutic freedom allowed under the Code of Professional Medical Conduct is taken into account by the fact that the responsibility for hemotherapy in each individual case lies with the attending physician, no matter whether this applies to the diagnosis, the patient counselling or the administration of the transfusion itself. The administration of blood products, whether in hospital or a doctor's office, must follow certain quality-assumed rules governing transfusions as stipulated by the Transfusion Law. The responsibility for establishing regulations for hemotherapy and the introduction of a quality assurance system lies with the management of the treatment centre who appoint a specific physician as the hemovigilant ('Transfusionsverantwortlichen') who is responsible for meeting both these duties. The hemovigilant must be assisted by physicians specially appointed for transfusion measures (Transfusionsbeauftragte) who are responsible for the implementation of the hemotherapy regulations and quality assurance measures in the individual medical departments. As it is the hospital management's responsibility to ensure quality assurance, its duty also extends to monitoring the quality assurance system. Therefore a quality manager ('Qualitätsbeauftragter') will have to be appointed who must not be subject to directives. In case the management of the patient care centre does not fulfill the legal requirements or, for example, does not take action when shortcomings are discovered by the hemovigilant or quality manager that can only be dealt with by the management, then the organisational responsibility lies with the hospital management. Experience to date has demonstrated the success of the Transfusion Law. Whereas previously hospital managements have often failed to respond to suggestions for change or improvement, their attention may now be drawn to this law. This has led to blood products being increasingly used according to the same standards and keeping transfusing physicians on safe legal ground.

摘要

本文探讨了在实施血液治疗措施过程中医生的责任。自1998年7月1日起,一部《输血法》(“Transfusionsgesetz”)根据德国医学协会和保罗·埃利希研究所制定的指南对德国血液制品的临床使用进行规范,这些指南会根据当前的专业知识和技术定期修订和调整。《医学职业行为准则》所允许的治疗自由体现在,每一个病例的血液治疗责任都在于主治医生,无论这涉及诊断、患者咨询还是输血本身的实施。无论是在医院还是在医生办公室,血液制品的使用都必须遵循《输血法》规定的某些假定质量规则。制定血液治疗法规和引入质量保证体系的责任在于治疗中心的管理层,他们指定一名特定的医生作为血液警戒员(“Transfusionsverantwortlichen”),该医生负责履行这两项职责。血液警戒员必须得到专门指定负责输血措施的医生(“Transfusionsbeauftragte”)的协助,这些医生负责在各个医疗科室实施血液治疗法规和质量保证措施。由于确保质量保证是医院管理层的责任,其职责还延伸至对质量保证体系的监督。因此,必须任命一名质量经理(“Qualitätsbeauftragter”),且该经理不得受指令约束。如果患者护理中心的管理层未满足法律要求,或者例如在血液警戒员或质量经理发现只能由管理层处理的缺陷时不采取行动,那么组织责任就在于医院管理层。迄今为止的经验证明了《输血法》的成功。以前医院管理层常常对变革或改进建议不予回应,而现在他们可能会关注这部法律。这使得血液制品越来越多地按照相同标准使用,并使输血医生处于安全的法律地位。

相似文献

1
[Risk management from the perspective of the hematologist].血液科医生视角下的风险管理
Z Arztl Fortbild Qualitatssich. 2003 Nov;97(8-9):618-21.
2
[The origin of informed consent].[知情同意的起源]
Acta Otorhinolaryngol Ital. 2005 Oct;25(5):312-27.
3
[Guidelines of the German Medical Association for Therapy with Blood Components and Plasma Derivatives--an introduction. Evidence-based recommendations for the risk-benefit analysis in hemotherapy].[德国医学协会血液成分与血浆衍生物治疗指南——引言。血液疗法中基于证据的风险效益分析建议]
Anasthesiol Intensivmed Notfallmed Schmerzther. 2009 Mar;44(3):186-97; quiz 199. doi: 10.1055/s-0029-1215550. Epub 2009 Mar 5.
4
[The responsibility of the physician prescriber of blood products].[血液制品开具处方医师的职责]
Transfus Clin Biol. 2004 Oct;11(4):221-7. doi: 10.1016/j.tracli.2004.09.007.
5
Blood transfusion in Europe: basic principles for initial and continuous training in transfusion medicine: an approach to an European harmonisation.欧洲的输血:输血医学初始培训与持续培训的基本原则:实现欧洲协调统一的方法
Transfus Clin Biol. 2006 Nov;13(5):282-5; quiz 286-9. doi: 10.1016/j.tracli.2006.11.004. Epub 2006 Dec 29.
6
[Quality assurance in blood transfusion].[输血中的质量保证]
Ann Pharm Fr. 2002 Sep;60(5):318-25.
7
[Quality assurance management system for therapy with blood and blood products].[血液及血液制品治疗的质量保证管理体系]
Anasthesiol Intensivmed Notfallmed Schmerzther. 1998 Oct;33(10):664-5. doi: 10.1055/s-2007-994830.
8
A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.一个就注意力缺陷/多动障碍的诊断和管理达成社区共识的过程。
Pediatrics. 2005 Jan;115(1):e97-104. doi: 10.1542/peds.2004-0953.
9
[Risk management as a means of quality assurance in the hospital].[风险管理作为医院质量保证的一种手段]
Z Arztl Fortbild Qualitatssich. 1999 Jan;93(1):57-62.
10
[The transfusion law in Germany--an assessment].[德国的输血法——一项评估]
Zentralbl Chir. 2003 Jun;128(6):459-61. doi: 10.1055/s-2003-40617.